Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus target price of $10.00 for the company and are expecting that the company will post ($0.69) EPS for the current quarter, according to Zacks. Zacks has also given Diffusion Pharmaceuticals an industry rank of 62 out of 256 based on the ratings given to related companies.
Several research analysts have recently commented on DFFN shares. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. HC Wainwright reissued a “buy” rating on shares of Advanced Emissions Solutions in a research note on Wednesday, March 20th.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09. Equities analysts anticipate that Diffusion Pharmaceuticals will post -2.27 EPS for the current fiscal year.
An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP bought a new stake in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned 0.95% of Diffusion Pharmaceuticals at the end of the most recent quarter. 6.20% of the stock is currently owned by institutional investors.
Diffusion Pharmaceuticals Company Profile
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Read More: What is the outlook for the FAANG stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.